{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Imagerie tridimensionnelle : Questions médicales les plus fréquentes",
"headline": "Imagerie tridimensionnelle : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Imagerie tridimensionnelle : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-18",
"dateModified": "2025-02-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Imagerie tridimensionnelle"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Traitement d'image par ordinateur",
"url": "https://questionsmedicales.fr/mesh/D007091",
"about": {
"@type": "MedicalCondition",
"name": "Traitement d'image par ordinateur",
"code": {
"@type": "MedicalCode",
"code": "D007091",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "L01.224.308"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Imagerie tridimensionnelle",
"alternateName": "Imaging, Three-Dimensional",
"code": {
"@type": "MedicalCode",
"code": "D021621",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Quan Yuan",
"url": "https://questionsmedicales.fr/author/Quan%20Yuan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Yasashri Ranathunga",
"url": "https://questionsmedicales.fr/author/Yasashri%20Ranathunga",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Wayne State University, Detroit, Michigan 48202, USA."
}
},
{
"@type": "Person",
"name": "Suk Kyoung Lee",
"url": "https://questionsmedicales.fr/author/Suk%20Kyoung%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Wayne State University, Detroit, Michigan 48202, USA."
}
},
{
"@type": "Person",
"name": "Wen Li",
"url": "https://questionsmedicales.fr/author/Wen%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Wayne State University, Detroit, Michigan 48202, USA."
}
},
{
"@type": "Person",
"name": "Myungjin Cho",
"url": "https://questionsmedicales.fr/author/Myungjin%20Cho",
"affiliation": {
"@type": "Organization",
"name": "School of ICT, Robotics and Mechanical Engineering, Institute of Information and Telecommunication Convergence (IITC), Hankyong National University, 327 Chungang-ro, Anseong 17579, Kyonggi-do, Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cellular and Molecular Diversity in Scleroderma.",
"datePublished": "2022-08-06",
"url": "https://questionsmedicales.fr/article/35940960",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.smim.2022.101648"
}
},
{
"@type": "ScholarlyArticle",
"name": "Spatial Transcriptomics Identifies Cellular and Molecular Characteristics of Scleroderma Skin Lesions: Pilot Study in Juvenile Scleroderma.",
"datePublished": "2024-08-23",
"url": "https://questionsmedicales.fr/article/39273131",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms25179182"
}
},
{
"@type": "ScholarlyArticle",
"name": "Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-Centered Intervention Network Cohort Study.",
"datePublished": "2022-05-11",
"url": "https://questionsmedicales.fr/article/33527717",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/acr.24567"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pulmonary Hypertension in Scleroderma- Evaluation and Management.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36163292",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.disamonth.2022.101468"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.",
"datePublished": "2022-10-14",
"url": "https://questionsmedicales.fr/article/36244404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.chest.2022.09.044"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Sciences de l'information",
"item": "https://questionsmedicales.fr/mesh/D007254"
},
{
"@type": "ListItem",
"position": 3,
"name": "Méthodologies informatiques",
"item": "https://questionsmedicales.fr/mesh/D003205"
},
{
"@type": "ListItem",
"position": 4,
"name": "Traitement d'image par ordinateur",
"item": "https://questionsmedicales.fr/mesh/D007091"
},
{
"@type": "ListItem",
"position": 5,
"name": "Imagerie tridimensionnelle",
"item": "https://questionsmedicales.fr/mesh/D021621"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Imagerie tridimensionnelle - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Imagerie tridimensionnelle",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Imagerie tridimensionnelle",
"description": "Quels examens utilisent l'imagerie 3D ?\nComment l'imagerie 3D aide-t-elle au diagnostic ?\nL'imagerie 3D est-elle utilisée en oncologie ?\nPeut-on détecter des anomalies avec l'imagerie 3D ?\nL'imagerie 3D est-elle utile pour les fractures ?",
"url": "https://questionsmedicales.fr/mesh/D021621?mesh_terms=Scleroderma,+Systemic&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Imagerie tridimensionnelle",
"description": "Quels symptômes peuvent nécessiter une imagerie 3D ?\nL'imagerie 3D peut-elle aider à évaluer des douleurs abdominales ?\nQuels symptômes cardiaques peuvent être évalués par imagerie 3D ?\nL'imagerie 3D est-elle utile pour les troubles respiratoires ?\nPeut-on détecter des anomalies cérébrales avec l'imagerie 3D ?",
"url": "https://questionsmedicales.fr/mesh/D021621?mesh_terms=Scleroderma,+Systemic&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Imagerie tridimensionnelle",
"description": "L'imagerie 3D peut-elle aider à la détection précoce des maladies ?\nComment l'imagerie 3D contribue-t-elle à la prévention des cancers ?\nPeut-on utiliser l'imagerie 3D pour le dépistage ?\nL'imagerie 3D aide-t-elle à évaluer les risques cardiovasculaires ?\nPeut-on prévenir des maladies avec l'imagerie 3D ?",
"url": "https://questionsmedicales.fr/mesh/D021621?mesh_terms=Scleroderma,+Systemic&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Imagerie tridimensionnelle",
"description": "L'imagerie 3D est-elle utilisée pour planifier des interventions chirurgicales ?\nComment l'imagerie 3D aide-t-elle en radiothérapie ?\nPeut-on utiliser l'imagerie 3D pour guider des biopsies ?\nL'imagerie 3D est-elle utile pour le suivi des traitements ?\nPeut-on utiliser l'imagerie 3D pour des traitements non invasifs ?",
"url": "https://questionsmedicales.fr/mesh/D021621?mesh_terms=Scleroderma,+Systemic&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Imagerie tridimensionnelle",
"description": "Quelles complications peuvent survenir avec l'imagerie 3D ?\nL'imagerie 3D peut-elle causer des effets secondaires ?\nY a-t-il des risques liés à l'utilisation d'agents de contraste ?\nL'imagerie 3D peut-elle entraîner des faux positifs ?\nQuelles sont les complications possibles après une biopsie guidée par imagerie 3D ?",
"url": "https://questionsmedicales.fr/mesh/D021621?mesh_terms=Scleroderma,+Systemic&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Imagerie tridimensionnelle",
"description": "Quels facteurs augmentent le besoin d'imagerie 3D ?\nL'âge est-il un facteur de risque pour l'imagerie 3D ?\nLe tabagisme influence-t-il le besoin d'imagerie 3D ?\nLes antécédents médicaux influencent-ils l'imagerie 3D ?\nY a-t-il des facteurs environnementaux affectant l'imagerie 3D ?",
"url": "https://questionsmedicales.fr/mesh/D021621?mesh_terms=Scleroderma,+Systemic&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Quels examens utilisent l'imagerie 3D ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La tomodensitométrie (CT) et l'IRM sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Comment l'imagerie 3D aide-t-elle au diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet une visualisation détaillée des organes et des tissus, facilitant le diagnostic."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D est-elle utilisée en oncologie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est essentielle pour localiser et évaluer les tumeurs."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies avec l'imagerie 3D ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de détecter des anomalies structurelles avec précision."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D est-elle utile pour les fractures ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à visualiser les fractures complexes et leur impact sur les tissus environnants."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent nécessiter une imagerie 3D ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs persistantes, des anomalies visibles ou des symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D peut-elle aider à évaluer des douleurs abdominales ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'identifier des problèmes comme des tumeurs ou des malformations."
}
},
{
"@type": "Question",
"name": "Quels symptômes cardiaques peuvent être évalués par imagerie 3D ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs thoraciques ou des palpitations peuvent nécessiter une évaluation."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D est-elle utile pour les troubles respiratoires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à visualiser les poumons et détecter des anomalies comme des nodules."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies cérébrales avec l'imagerie 3D ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est efficace pour visualiser des anomalies comme des tumeurs ou des AVC."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D peut-elle aider à la détection précoce des maladies ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de détecter des maladies à un stade précoce, améliorant les chances de traitement."
}
},
{
"@type": "Question",
"name": "Comment l'imagerie 3D contribue-t-elle à la prévention des cancers ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de surveiller les patients à risque et de détecter des anomalies précoces."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie 3D pour le dépistage ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est utilisée pour le dépistage de certaines maladies comme le cancer du sein."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D aide-t-elle à évaluer les risques cardiovasculaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'évaluer l'état des artères et de détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir des maladies avec l'imagerie 3D ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indirectement, en permettant une détection précoce et un suivi régulier."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D est-elle utilisée pour planifier des interventions chirurgicales ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de planifier avec précision les interventions chirurgicales."
}
},
{
"@type": "Question",
"name": "Comment l'imagerie 3D aide-t-elle en radiothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de cibler précisément les tumeurs tout en épargnant les tissus sains."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie 3D pour guider des biopsies ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à localiser précisément les zones à biopsier."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D est-elle utile pour le suivi des traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'évaluer l'efficacité des traitements au fil du temps."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie 3D pour des traitements non invasifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est utilisée pour des techniques comme l'ablation par radiofréquence."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'imagerie 3D ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques aux agents de contraste ou des effets secondaires liés à l'exposition."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D peut-elle causer des effets secondaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, notamment des effets liés à l'exposition aux radiations en cas de CT."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques liés à l'utilisation d'agents de contraste ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions allergiques ou des problèmes rénaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "L'imagerie 3D peut-elle entraîner des faux positifs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent être détectées qui ne sont pas cliniquement significatives."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles après une biopsie guidée par imagerie 3D ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements ou des infections peuvent survenir après la procédure."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le besoin d'imagerie 3D ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Antécédents familiaux de maladies, symptômes persistants ou exposition à des risques environnementaux."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour l'imagerie 3D ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées sont plus susceptibles de nécessiter des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le besoin d'imagerie 3D ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il augmente le risque de maladies pulmonaires nécessitant une évaluation."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils l'imagerie 3D ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies peuvent justifier des examens d'imagerie réguliers."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux affectant l'imagerie 3D ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des substances toxiques peut augmenter le besoin d'examens."
}
}
]
}
]
}
With the increasing armamentarium of high-throughput tools available at manageable cost, it is attractive and informative to determine the molecular underpinnings of patient heterogeneity in systemic ...
Juvenile localized and systemic scleroderma are rare autoimmune diseases which cause significant disability and morbidity in children. The mechanisms driving juvenile scleroderma remain unclear, neces...
To support physical activity among people with systemic sclerosis (SSc [scleroderma]), we sought to determine the prevalence and importance of barriers and the likelihood of using possible facilitator...
We invited 1,707 participants from an international SSc cohort to rate the importance of 20 barriers (14 medical, 4 social or personal, 1 lifestyle, and 1 environmental) and the likelihood of using 91...
Among 721 respondents, 13 barriers were experienced by ≥25% of participants, including 2 barriers (fatigue and Raynaud's phenomenon) rated "important" or "very important" by ≥50% of participants, 7 ba...
Medical-related physical activity barriers were common and considered important. Facilitators considered as most likely to be used involved adapting exercise, taking care of one's body, keeping warm, ...
Pulmonary Arterial Hypertension (PAH) is a clinical syndrome consisting of physiologic/hemodynamic criteria that are a consequence of several etiologies. Systemic Sclerosis (SSc), one of the most comm...
Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort....
Do enrichment strategies for progressive ILD impact efficacy, representativeness, and feasibility in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database?...
We applied the inclusion criteria of major recent SSc-ILD trials (Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis [focuSSced], Scleroderma Lung Study II [SLS II...
In total, 2,258 patients with SSc-ILD were included: 31.2% of the patients met SENSCIS criteria; 5.8% of the patients met SLS II criteria; 1.6% of the patients met focuSSced criteria, and 67.7% (1,529...
The application of enrichment criteria from previous clinical trials showed enrichment for progression with variable success, which led to selected patient populations reducing feasibility of recruitm...
Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non-SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with...
Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confi...
Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36-1.60; P < 0...
Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk....
One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the dia...
There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows...
ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future res...
The mechanisms of systemic autoimmune diseases (ADs) are still not clearly understood. Understanding the etiology of systemic ADs and identifying new therapeutic targets require a systems science appr...
People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in pe...
The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analys...
Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by...
People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering t...
Systemic sclerosis (SSc) is a rare auto-immune disease, affecting principally women between 40 and 60 years old. It is caracterised by a cutaneous and visceral fibrosis, an alteration of the microvasc...
We have analysed the data of a retrospective and bicentrique cohort, from the internal medicine unit of Hôpital Nord in Marseille and from the internal medicine unit of the Hôpital Sainte-Anne in Toul...
The cohort included 151 patients including 134 limited cutaneous SSc. Fifty-two (34.4%) patients presented at least one associated auto-immune or inflammatory disease. The association of two connectiv...
SSc is often associated with other autoimmune diseases. This interrelation between associated pathologies and SSc, modifying sometimes the evolution of SSc, enhances the need of a personalized follow-...